Introduction to Apelis (Abolib) and applicable groups

Apelvis, as a new targeted therapy drug, has attracted widespread attention in the field of breast cancer treatment in recent years. Its unique pharmacological mechanism and significant therapeutic effect bring new treatment options to patients with advanced breast cancer. The drug was developed and produced by Novartis Pharmaceuticals. It has been approved by the U.S.FDA and has not yet been marketed in China.

1. Introduction to Apelis

Alpelisib, the English name isAlpelisib, the trade name is Piqray, which is a targeted therapy drug for advanced breast cancer. It inhibits the activity of PIK3CA enzyme and blocks the growth signals of cancer cells, thereby inhibiting the progression of tumors. Apelix's mechanism of action targets the PIK3CA mutation that is common in breast cancer cells. This mutation is relatively common in advanced breast cancer and is one of the important factors leading to abnormal proliferation and survival of breast cancer cells. Clinically, the drug has been proven to have significant efficacy and good safety.

Apelix is administered orally, usually once daily, and the dosage is determined by the doctor based on the patient's specific conditions. During the treatment process, patients need to strictly follow the doctor's instructions to take the medication to ensure the effectiveness and safety of the medication.

2. Applicable people

Apelvis is specifically indicated for use in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. This treatment regimen is detected by an FDA-approved test at or after progression on an endocrine-based treatment regimen. For such patients, the combination treatment of apelvis and fulvestrant has a significant therapeutic effect.

It should be emphasized that before using Apelvis, patients should consult their doctor and undergo a comprehensive physical examination to ensure that the drug is suitable for their condition. At the same time, during the treatment process, patients should pay close attention to their physical condition, and if they have any discomfort or side effects, they should promptly inform their doctor and seek help.

In short, apelvis, as a new breast cancer treatment drug, provides a new treatment option for patients with advanced breast cancer. Its unique pharmacological mechanism and significant therapeutic effect bring new hope to breast cancer patients. At present, Apelvis is only sold overseas. The Indian original version is priced at about 5,000 yuan per box, and the Laos imitation version of the same specifications is about more than 2,000 yuan. Patients should choose according to their needs.